anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prostate biopsy to diagnose or exclude cancer is currently performed an estimated one million times annually worldwide. In this method, the operator images the prostate using ultrasound, as performed for the past several decades; while thus viewing the prostate, the MRI of that prostate, which is performed beforehand and stored in the device, is fused with real-time ultrasound using a digital overlay, allowing the target(s), previously delineated by a radiologist, to be brought into the aiming mechanism of the ultrasound machine. The fusion results in creation of a three-dimensional reconstruction of the prostate, and on the reconstructed model, the aiming and tracking of biopsy sites occurs. This method needs for sedation/general/ spinal anesthesia because of patient discomfort with the transperineal approach of the biopsy needle passing through the perineum.

Even though the MRI/ultrasound fusión prostate biopsy is widespread used, the anaesthetic techniques for this procedure are not standardised. Hyperbaric prilocaine is an amide-type local anesthetic widely used in short surgical procedures showing its efficacy for outpatient surgery. The proposed intrathecal doses of prilocaine for various surgical procedures range from 10 to 80 mg. Thus, even though the drug is in clinical use, optimal doses of HP required for specific types of surgery warrant further refinement. The aim of the present study was to determine the ED50 and ED90 of intrathecal HP for patients undergoing undergoing ambulatory MRI/ultrasound fusión prostate biopsy.
The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.
Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
The present invention relates to an agent for acne elimination, which is a traditional Chinese medicine health-care beautifying medicine used for eliminating the human body's acne. The agent for acne elimination mainly contains a certain amount of 9 Chinese herbal medicines such as chrysanthemum, cortex moutan, arnebia root, largetrifoliolious bugbane rhizome, etc. The present invention aims to solve the utility model defects that the existing method of external treatment for the acne has the defects of long treating period, low effective rate and no obvious improvement on the pigmentation and the scars formed on the face, and is based on the principle of treating the root cause. The present invention uses the mode of adjusting the incretion. After dozens of acne patient's trial drinking, the prepared acne-eliminating health-care beautifying tea has the effective rate of 95% to 99% in 10 to 20 days, and obviously reduces the pigmentation and the scars on the face after 30 days. The health-care treating effect is obviously increased, and the beautifying effect is obtained.
This study investigated the sleep quality and its psychological correlates among hospitalized antepartum women. A cross-sectional correlation study design and convenience sampling were conducted in the gynecological ward of a medical center in northern Taiwan. A total of 101 hospitalized antepartum women were recruited. A self-administered structured questionnaire including demographic profiles, State-Trait Anxiety Inventory (STAI), Antepartum Hospital Stressors Inventory (AHSI), and Pittsburgh Sleep Quality Index (PSQI) was used for the study. Bivariate and multiple linear regressions were used to analyze the data. A majority of the participants had poor sleep quality (82.8%), based on the global PSQI score. Sleep quality correlated with age, marital and employment status, parity, method of conception, multiple gestation, history of pregnant complications, anxiety symptom and hospital stressors which explained 21% of the variance in sleep quality. This study found a high prevalence of poor sleep quality in hospitalized antepartum women. Anxiety symptom was a significant predictor of sleep quality. Healthcare providers should be encouraged to assess sleep and emotional status in antepartum women during hospitalization and provide them appropriate interventions to improve sleep and reduce anxiety symptoms and hospital stressors.
Earthquake is the type of natural hazard with the highest mortality in the world and in Turkey. The majority of Turkey\'s population lives under the threat of earthquakes.It is necessary to adopt a risk management approach against earthquake danger and to raise conscious individuals.Thanks to earthquake education activities for students, earthquake awareness can be spread to students\' peers, families and teachers. In this way, the society can be resistant to the earthquake hazard.It is recommended that a combination of visual, audio and interactive tools be preferred and technology be used in earthquake education activities.In earthquake education activities, the use of mobile learning method has advantages such as eliminating time and space limitations, increasing equality of opportunity in education, supporting individualized learning and providing instant feedback.

This project will be carried out to examine the effect of the mobile earthquake education application developed for high school students on the students\' level of knowledge about earthquakes. The research will be conducted in two different schools in Konya in the 2023-2024 academic year.The population of the research is 9th grade students in both schools. The sample size was calculated with the Open epi and t was decided to 160 students, 80 experimental and 80 control. In order to prevent interaction between students, one of the schools involved in the research will be the experimental group and the other will be the control group. Groups will be determined with the lottery method.Three 9th grade students from each school will be included in the research. Three classes to be taken into groups in schools will be selected by simple random sampling method. The researcher will collect the pre-tests to all students who meet the research criteria and agree to participate in the study. The researcher will present 2 hours of basic earthquake education to both the experimental and control groups. The students in the experimental group will be registered on the mobile earthquake education. The students in the experimental group will use "mobile earthquake education" for 4 weeks. After 4 weeks, a posttest will be administered to all students in the experimental and control groups. To evaluate the permanence of the mobile earthquake education initiative, a post-test will be administered to participants 8 weeks after the application begins. As data collection form, sociodemographic characteristics survey form, earthquake risk perception scale, earthquake knowledge level survey will be used. The results will be presented with frequency distributions and mean±standard deviation. In the analysis, t test or Mann Whitney U Analysis will be used in independent groups and Variance Analysis or Friedman Analysis of Variance will be used in dependent groups.
Arm 1 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months.
Antimicrobial resistance (AMR) emerges as a severe crisis to public health and requires global action. The occurrence of bacterial pathogens with multi-drug resistance appeals to exploring alternative therapeutic strategies. Antivirulence treatment has been a positive substitute in seeking to circumvent AMR, which aims to target virulence factors directly to combat bacterial infections. Accumulated evidence suggests that plant-derived natural products, which have been utilized to treat infectious diseases for centuries, can be abundant sources for screening potential virulence-arresting drugs (VADs) to develop advanced therapeutics for infectious diseases. This review sums up some virulence factors and their actions in various species of bacteria, as well as recent advances pertaining to plant-derived natural products as VAD candidates. Furthermore, we also discuss natural VAD-related clinical trials and patents, the perspective of VAD-based advanced therapeutics for infectious diseases and critical challenges hampering clinical use of VADs, and genomics-guided identification for VAD therapeutic. These newly discovered natural VADs will be encouraging and optimistic candidates that may sustainably combat AMR.
The present invention relates to a cigarette toxin resisting health food preparation and a preparing process thereof, which belongs to the technical field of health foods and is used for solving the problems of harm to human bodies. The preparation is composed of rumex acetosa, humid euphorbia and orange peel, and various preparation forms can be obtained through the procedures of screening, compounding, pulverization, extrusion, etc. The health food preparation is composed of the essential ingredients of a group of natural plants and does not contain any chemical substance, such as additives, antiseptics, etc. Researches and animal experiments for years show that the preparation has good effect on eliminating or relieving the harm of nicotine to the human bodies and can effectively remove phlegm in respiratory systems and reduce the disease incidence rate of the respiratory system. The present invention can be taken by smokers as a cigarette mate for a long time. The preparation also has the effects of relaxing tendons, activating blood circulation, lowering blood pressure, removing toxin and nursing faces, and has no toxic side effect; the preparation can also taken by common people as a health food. The preparation has the advantages of various preparation forms, comfortable mouth feel and convenient administration.
Background: Sex Chromosome Trisomies (SCT) including Klinefelter (XXY), Trisomy X (XXX), and XYY syndromes occur in 1 out of every 500 births and are associated with a broad phenotypic spectrum including increased risk for developmental delays (DD), language/learning disorders, and autism spectrum disorder (ASD). XXY is also associated with testicular failure, XXX increases risk for ovarian failure, and disorders of insulin resistance and other medical problems resulting in increased morbidity and mortality occur in all 3 SCTs. Historically, less than 10% of SCT diagnoses occur in childhood, however the rate of newborns with SCT has markedly increased with new noninvasive prenatal cell-free DNA (cfDNA) screening. SCT natural history research is limited to studies from the 1970's, and the investigators have little knowledge of early predictors of the wide heterogeneity in later outcomes. The high risk for DD in SCT suggests that newborn screening may improve identification for DD and timely initiation of interventions. However, it is not clear whether all SCT infants indeed require intensive developmental assessments and therapies, or if primary care screenings are sufficient to identify those in need. The surge in prenatal SCT diagnoses from cfDNA methods provides an opportunity for longitudinal study of a cohort of infants to explore natural history, and to improve care.

Aims: This study aims to: (1) describe and compare the natural history of neurodevelopment, health and early gonadal function in infants with the 3 SCT conditions through a national prospective eXtraordinarY Babies Study in partnership with the Newborn Screening Translational Research Network (NBSTRN), (2) identify early predictors of poor neurodevelopmental and cardiometabolic outcomes, and (3) evaluate the sensitivities of common primary care developmental screening measures to detect DD and ASD in this high-risk population to inform recommendations for an early neurodevelopmental care protocol.

Approach: Infants with a prenatal diagnosis of XXY, XYY, or XXX will be followed prospectively every 6-12 months for 2-4 years at 2 eXtraordinarY Kids Clinic sites. Demographics, health history, development, interventions, and social/family history will be collected. Assessments will include: (1) measures of cognitive, language, social, motor, and adaptive function, (2) physical exam, gonadal function labs, cardiometabolic measures, and body composition, and (3) quality of life outcomes. Impact: Prospective study of the natural history of prenatally diagnosed infants with SCT will allow investigation of important questions to inform newborn screening considerations, such as the interplay between early hormonal profiles and developmental outcomes. Results will be immediately relevant for counseling and establishing evidence-based care guidelines for the rapidly increasing rate of SCT diagnoses from cfDNA screening. Results will serve as the basis for ongoing longitudinal studies of health and psychological outcomes of SCTs through the lifespan.
The invention relates to the fields of biotechnology and medicine, more particularly to the production and use of single-domain nanobodies for detecting and blocking infection caused by pathogenic microorganisms, in particular  Chlamydia trachomatis . A nanobody is claimed which specifically binds to the  Chlamydia trachomatis  surface antigen and has the amino acid sequence SEQ ID NO:2. Further, a nanobody is claimed which specifically binds to the  Chlamydia trachomatis  surface antigen and has the amino acid sequence SEQ ID NO:4. The nanobody having the amino acid sequence SEQ ID NO:2 inhibits the development of chlamydial infection caused by  Chlamydia trachomatis . The nanobody having the amino acid sequence SEQ ID NO:4 inhibits the development of chlamydial infection caused by  Chlamydia trachomatis . A method is claimed for inhibiting in vitro the development of chlamydial infection caused by  Chlamydia trachomatis , which includes pre-treating  Chlamydia trachomatis  elementary bodies with a therapeutically effective amount of the nanobody having the amino acid sequence SEQ ID NO:2 before adding said elementary bodies to the target cells to be infected. A method is also claimed for inhibiting  in vitro  the development of chlamydial infection caused by  Chlamydia trachomatis , which includes pre-treating  Chlamydia trachomatis  elementary bodies with a therapeutically effective amount of the nanobody having the amino acid sequence SEQ ID NO:4 before adding said elementary bodies to the target cells to be infected.
This is a multi-center randomized phase III clinical trial, the Inhibitor Prevention Trial, in which consecutive hemostatic agents will be compared using adaptive design to prevent inhibitors in patients with severe hemophilia A. This adaptive design is necessary as randomized trials in rare diseases are otherwise not possible. This adaptive design is necessary as randomized trials in rare diseases are otherwise not possible. The INHIBIT Clinical Trials Platform includes two linked trials, the Inhibitor Prevention Trial (Prevention Trial) and the Inhibitor Eradication Trial (Eradication Trial) that will be conducted at up to 41 U.S. hemophilia treatment centers (HTCs) affiliated with universities. The Inhibitor Prevention Trial is a 48-week randomized phase III trial, in which 66 previously untreated patients (PUPs) with severe hemophilia A will be enrolled. Subjects will include children from 4 months of age up to 4 years of age who have not been previously treated with clotting factor. Once enrolled, subjects who meet all the inclusion and none of the exclusion criteria will be randomized to preemptive weekly Eloctate (rFVIIIFc) vs. weekly Emicizumab (Hemlibra) to prevent inhibitor formation, defined as anti-FVIII \>= 0.6 BU. Blood draws will be minimized to 6 timepoints, pre, 4, 12, 24, 36, and 48 weeks, and validated for small volumes, 3.8 cc (¾ tsp) each. The Inhibitor Prevention Trial is considered greater than minimal risk as study drug is given before the first bleed and special inhibitor studies are obtained. (NB: The Inhibitor Prevention Trial (PRO19040140) is linked to the Inhibitor Eradication Trial (PRO19070080), as part of the INHIBIT Clinical Trials Platform, with both trials will be conducted efficiently in the same hemophilia treatment centers (HTCs), with the same MDs, coordinators, visit frequency, blood sampling, and assays.
Advances in pediatric (cardiac) surgery, interventional techniques and medical care have improved survival for children born with congenital heart disease. Assessment of blood flow and pressures within the heart plays an integral role in the management of patients with congenital or acquired structural heart disease aiding with diagnoses, surveillance for complications, in relation to surgical or catheter procedures, and for therapeutic decision making. Current gold standard, direct intracardiac measurement of flow and pressures is an invasive procedure, while non-invasive echography-Doppler is limited by poor acoustic windows and operator dependency.

Therefore, cardiac MRI (cMRI) has been recommended as an important alternative in imaging of pediatric heart disease. Current clinical standard for MR flow imaging is 2-dimensional providing flow in a single cross-sectional plane. Current clinical CMR protocols in pediatric congenital heart disease are time consuming, depend on technician's experience and require direct supervision by an experienced cardiovascular imaging specialist. 4D Flow is a new approach for cMRI that might overcome these disadvantages. It allows scanning of the entire chest in approximately 7 minutes (depending on field of view, heart rate and resolution). The images can be off-line reconstructed in any plane, avoiding the need to precisely define crosssectional planes during acquisition for each vessel. Owing to time resolved visualizations of intracardiac flow dynamics occult jets or dynamic jets might be more likely to be detected. Potential disadvantages, rsp. potential advantages to be confirmed include lower temporal resolution of 4D sequences than current 2D sequences, unknown consequences of gradient artefacts induced by new velocity encoding schemes and diagnostic plausibility of disease related image features .
Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
Perineural invasion (PNI) is a new approach of cervical cancer invasion and metastasis, involving the cross-talk between tumor and nerve. However, the initiating signals and cellular interaction mechanisms of PNI remain largely elusive. The nerve-sparing radical hysterectomy (NSRH) proposed to improve postoperative quality of life is only applicable to cervical cancer patients without PNI. Therefore, it is important to elucidate the underlying mechanisms initiating PNI, and suggest the effective biomarkers to predict PNI before NSRH surgery. Here, we found that PNI is the characteristic of advanced cervical cancer, and Schwann cells were the antecedent cells that initiating PNI. Further, neuropeptide neuromedin B (NMB) produced by cervical cancer cells was determined to induce PNI by reprogramming Schwann cells, including driving their morphological and transcriptional changes, promoting their proliferation and migration, and initiating PNI by secreting CCL2 and directing axon regeneration. Mechanistically, cervical cancer cells-produced NMB activated its receptor NMBR in Schwann cells, and opened the T-type calcium channels to stimulate Ca2+ influx through PKA signaling, which could be blocked by the inhibitor. Clinically, combined examination of serum NMB and CCL2 levels was suggested to effectively predict PNI in cervical cancer patients. Our data demonstrate that cervical cancer-produced NMB initiates the reprograming of Schwann cells, which then direct axon regeneration, thus causing PNI onset. The elevated serum NMB and CCL2 levels may be useful for the decision-making to nerve sparing during hysterectomy surgery of cervical cancer patients.
Some patients benefit from a treatment while others may do so less or do not benefit at all. We have previously developed a two-stage network meta-regression prediction model that synthesized randomized trials and evaluates how treatment effects vary across patient characteristics. In this article, we extended this model to combine different sources of types in different formats: aggregate data (AD) and individual participant data (IPD) from randomized and non-randomized evidence. In the first stage, a prognostic model is developed to predict the baseline risk of the outcome using a large cohort study. In the second stage, we recalibrated this prognostic model to improve our predictions for patients enrolled in randomized trials. In the third stage, we used the baseline risk as effect modifier in a network meta-regression model combining AD, IPD randomized clinical trial to estimate heterogeneous treatment effects. We illustrated the approach in the re-analysis of a network of studies comparing three drugs for relapsing-remitting multiple sclerosis. Several patient characteristics influence the baseline risk of relapse, which in turn modifies the effect of the drugs. The proposed model makes personalized predictions for health outcomes under several treatment options and encompasses all relevant randomized and non-randomized evidence.
The invention discloses a carrier pigeon newcastle disease virus genetic engineering transformation attenuated strain, a preparation method and application thereof. Specifically, the reverse genetic operation technology is applied, site-directed mutation is carried out on amino acids of 3 cleavage sites of F protein of a carrier pigeon newcastle disease virus strain (PNDV-YQ strain), full-length cDNA plasmid pOK-YQ of low virulence genes is constructed and obtained in a segmented cloning mode, ORF genes of NP, P and L of PNDV-YQ strain are cloned to eukaryotic expression vectors pCIneo respectively, and helper plasmids pCI-NP, pCI-P and pCI-L are constructed and obtained. After cotransfection of BSR-T7 cells with the full-length plasmid and the helper plasmid, the recombinant attenuated virus, i.e. pigeon Newcastle disease virus (PNDV-aYQ strain) is rescued. The strain is a low-pathogenicity or non-pathogenicity strain, and has good proliferation characteristics and stable genetic characteristics. Compared with the existing newcastle disease vaccine, the inactivated vaccine prepared by the virus strain has the advantages of low side reaction, early immune generation period and high protection rate.